General medical services

MGC Pharma's CannEpil® Now Accessible to UK Patients on Named Patient Request Basis

Retrieved on: 
Tuesday, April 11, 2023
Epilepsy, LSE, GMC, Ireland, MXC, General Medical Council, Marketing, Isabella Tree, IMP, ASX, Hemispherectomy, Republic of Ireland, General medical services, Patient, OTC, Seizure, Safety, Pharmaceutical industry, Cannabidiol, CBD

LONDON, April 11, 2023 /PRNewswire/ -- MGC Pharmaceuticals Ltd. (LSE: MXC), (ASX: MXC), (OTC: MGCLF), a European based pharmaceutical company specializing in the development and supply of affordable, ethically produced plant-inspired medicines, announces that its proprietary product CannEpil® is now available to patients in the UK by Named Patient Request.

Key Points: 
  • This underlines the potential of CannEpil®, an investigational medicinal product for patients suffering from refractory epilepsy, to make a significant impact in the UK market.
  • LONDON, April 11, 2023 /PRNewswire/ -- MGC Pharmaceuticals Ltd. (LSE: MXC), (ASX: MXC), (OTC: MGCLF), a European based pharmaceutical company specializing in the development and supply of affordable, ethically produced plant-inspired medicines, announces that its proprietary product CannEpil® is now available to patients in the UK by Named Patient Request.
  • MGC Pharma's CannEpil® is an investigational medicinal product (IMP) designed for patients suffering from refractory epilepsy, also known as drug-resistant epilepsy.
  • Roby Zomer, Managing Director and CEO of MGC Pharmaceuticals, commented: "The availability of CannEpil® by Named Patient Request marks a momentous breakthrough for MGC Pharma.

MGC Pharma's CannEpil® Now Accessible to UK Patients on Named Patient Request Basis

Retrieved on: 
Tuesday, April 11, 2023
Epilepsy, LSE, GMC, Ireland, MXC, General Medical Council, Marketing, Isabella Tree, IMP, ASX, Hemispherectomy, Republic of Ireland, General medical services, Patient, OTC, Seizure, Safety, Pharmaceutical industry, Cannabidiol, CBD

LONDON, April 11, 2023 /PRNewswire/ -- MGC Pharmaceuticals Ltd. (LSE: MXC), (ASX: MXC), (OTC: MGCLF), a European based pharmaceutical company specializing in the development and supply of affordable, ethically produced plant-inspired medicines, announces that its proprietary product CannEpil® is now available to patients in the UK by Named Patient Request.

Key Points: 
  • This underlines the potential of CannEpil®, an investigational medicinal product for patients suffering from refractory epilepsy, to make a significant impact in the UK market.
  • LONDON, April 11, 2023 /PRNewswire/ -- MGC Pharmaceuticals Ltd. (LSE: MXC), (ASX: MXC), (OTC: MGCLF), a European based pharmaceutical company specializing in the development and supply of affordable, ethically produced plant-inspired medicines, announces that its proprietary product CannEpil® is now available to patients in the UK by Named Patient Request.
  • MGC Pharma's CannEpil® is an investigational medicinal product (IMP) designed for patients suffering from refractory epilepsy, also known as drug-resistant epilepsy.
  • Roby Zomer, Managing Director and CEO of MGC Pharmaceuticals, commented: "The availability of CannEpil® by Named Patient Request marks a momentous breakthrough for MGC Pharma.

Duke T. Matsuyama, MD, is recognized by Continental Who's Who

Retrieved on: 
Thursday, December 1, 2022
Golf, Operation Iraqi Freedom documents, Fleet Marine Force, Multimedia, Laboratory, Health Professions Scholarship Program, California State University, Patient, American Osteopathic College of Radiology, Society, General medical services, Medical Center, Marine Corps Base Camp Lejeune, Camp Fallujah, MD, Fleet Marine Force insignia, United States Department of the Navy, American Osteopathic Association, American Society of Anesthesiologists, Judge Advocate General's Corps, U.S. Navy, Family, A.T. Still University, National Microbiology Laboratory, Continental, Hospital, Medical device, Osteopathic medicine in the United States

Dr. Matsuyama earned a Bachelor of Arts degree in Biological Sciences from California State University, Fullerton, in 1997.

Key Points: 
  • Dr. Matsuyama earned a Bachelor of Arts degree in Biological Sciences from California State University, Fullerton, in 1997.
  • He then earned his Doctor of Osteopathic Medicine Degree at Kirksville College of Osteopathic Medicine in Maryland in 2003.
  • Dr. Matsuyama completed an internship in Osteopathic Medicine and an Anesthesiology residency at Grandview Hospital and Medical Center in Dayton, Ohio.
  • He was awarded Preceptor of the Year in 2018 and recognized with a profile feature in Marquis Who's Who in 2021.

Duke T. Matsuyama is being recognized by Continental Who's Who

Retrieved on: 
Tuesday, May 17, 2022
Laboratory, Education, Operation Iraqi Freedom documents, Judge Advocate General's Corps, U.S. Navy, A.T. Still University, National Microbiology Laboratory, Fleet Marine Force, American Society of Anesthesiologists, Medicine, Marine Corps Base Camp Lejeune, Family, Health Professions Scholarship Program, American Osteopathic Association, Multimedia, Patient, Golf, Clinical Practice, Society, United States Department of the Navy, California State University, Camp Fallujah, American Osteopathic Association Bureau of Osteopathic Specialists, American Osteopathic College of Occupational & Preventive Medicine, General medical services, Medical Center, CA, Continental, Medical device, Osteopathic medicine in the United States

FAYETTEVILLE, N.C., May 17, 2022 /PRNewswire/ -- Duke T. Matsuyama is being recognized by Continental Who's Who as a Top Anesthesiologist in the Medical field and in acknowledgment of his work at Cumberland Anesthesia Associates.

Key Points: 
  • FAYETTEVILLE, N.C., May 17, 2022 /PRNewswire/ -- Duke T. Matsuyama is being recognized by Continental Who's Who as a Top Anesthesiologist in the Medical field and in acknowledgment of his work at Cumberland Anesthesia Associates.
  • Duke T. Matsuyama is a dedicated Anesthesiologist with a background in the United States Navy and Clinical Practice.
  • To begin his college education, Dr. Matsuyama earned a Bachelor of Arts degree in Biological Sciences from California State University, Fullerton, in 1997.
  • Dr. Matsuyama completed an internship in Osteopathic Medicine and an Anesthesiology residency at Grandview Hospital and Medical Center in Dayton, Ohio.

Lex A. Mitchell, MD, is recognized by Continental Who's Who

Retrieved on: 
Wednesday, January 19, 2022
Arkansas School for Mathematics, Sciences, and the Arts, HI, American Board of Radiology, Patient, American Board of Commissioners for Foreign Missions, Kaiser Permanente, PET, University, ABR, Injury, Medical imaging, Arkansas Tech University, Army of the United States, General medical services, Lucile Packard Children's Hospital, Medicare Physician Group Practice (PGP) Demonstration, Society, Magnetic resonance imaging, Continental, X-ray, Parent, Tripler Army Medical Center, CT, Education, Hospital, MD, Madigan Army Medical Center, Multimedia, Lieutenant colonel, Medicine, Radiological Society of North America, Brain, Mitchell, Mobile phone, Chemistry, Radiology

HONOLULU, Jan. 19, 2022 /PRNewswire/ -- Lex A. Mitchell, MD, is being recognized by Continental Who's Who as a Distinguished Radiologist for his many years of outstanding service in the field of Radiology.

Key Points: 
  • HONOLULU, Jan. 19, 2022 /PRNewswire/ -- Lex A. Mitchell, MD, is being recognized by Continental Who's Who as a Distinguished Radiologist for his many years of outstanding service in the field of Radiology.
  • As a highly trained radiologist with 16 years of experience, Dr. Mitchell treats patients at Kaiser Permanente Moanalua Medical Center in Honolulu, HI.
  • Dr. Mitchell has been in the position for two years, during which he has aided countless patients.
  • As a physician with Hawaii Permanente Medical Group, Dr. Mitchell is part of Hawaii's largest multispecialty group practice.

Contaminated Stethoscopes Pose an Infection Risk to Patients and a Legal Risk to Medical Professionals

Retrieved on: 
Thursday, August 5, 2021
MD, Chief executive officer, Human, Solution, Technology, Infection, Practice, Hygiene, Decision-making, Time, Health, Patient, COVID-19, CDC, Hand, Auscultation, SAN, Cardiology, Awareness, Risk, General medical services, Research, Compliance, Physician, Pharmaceutical industry, Medical device

"Failure to perform effective stethoscope hygiene between patients utterly undermines our hand hygiene efforts and practices," said Dr.

Key Points: 
  • "Failure to perform effective stethoscope hygiene between patients utterly undermines our hand hygiene efforts and practices," said Dr.
  • Dan Hannula, a co-author and medical malpractice legal expert, agrees with Dr. Amin on the potential vulnerability of healthcare providers.
  • The AseptiScope mission is to design, develop, manufacture and commercialize novel solutions that ensure "Infection Protection for Clinician & Patient."
  • AseptiScope and related logos are registered trademarks of AseptiScope, Inc.DiskCover and related logos are trademarks of AseptiScope, Inc.